VISIGALLI, DAVIDE
 Distribuzione geografica
Continente #
EU - Europa 1.616
Totale 1.616
Nazione #
IT - Italia 1.616
Totale 1.616
Città #
Genova 1.166
Rapallo 265
Genoa 183
Bordighera 2
Totale 1.616
Nome #
Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies 136
The diadenosine homodinucleotide P18 improves in vitro myelination in experimental Charcot-Marie-Tooth type 1A 129
Hind limb unloading of micemodulates gene expression at the protein and mRNA level in mesenchymal bonecells. 127
Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy 123
Alternative Splicing in the Human PMP22 Gene: Implications in CMT1A Neuropathy 110
Soluble Neuregulin1 is strongly up-regulated in the rat model of Charcot-Marie-Tooth 1A disease 108
The carboxyl terminal trimer of procollagen I induces pro-metastatic changes and vascularization in breast cancer cells xenografts 106
Oxydative phosphorylation in sciatic nerve myelin and its impairment in a model of dysmyelinating peripheral neuropathy 91
PMP22 messenger RNA levels in skin biopsies: Testing the effectiveness of a Charcot-Marie-Tooth 1A biomarker 90
P2X7 antagonists improve “in vitro” myelination in organotypic dorsal root ganglia (DRG) cultures from a rat model of CMT1A neuropathy 87
P2X7 antagonism in experimental CMT1A: a potential therapeutic strategy 87
Oxydative phosphorilation in sciatic nerve myelin and its impairment in a model of dysmyelinating peripheral neuropathy 81
P2X7 antagonists improve “in vitro” myelination in organotypic dorsal root ganglia (DRG) cultures from a rat model of CMT1A neuropathy 76
The diadenosine homodinucleotide P18 improvesin vitromyelination in experimental Charcot-Marie-Tooth type 1A 71
Exploiting Sphingo- and Glycerophospholipid Impairment to Select Effective Drugs and Biomarkers for CMT1A 58
P2X7 RECEPTOR IMPLICATION IN CHARCOT-MARIE-TOOTH TYPE 1A (CMT1A) 56
P2X7 TARGETING IMPROVES IN VITRO MYELINATION IN EXPERIMENTAL CHARCOT-MARIE-TOOTH TYPE 1A (CMT1A) 52
null 48
DEVELOPMENT AND VALIDATION OF A BIOMARKERS PANEL TO CAPTURE PATHOPHYSIOLOGICAL HETEROGENEITY OF GBS AND CIDP PATIENTS 14
Case Report: Post-COVID-19 Vaccine Recurrence of Guillain-Barré Syndrome Following an Antecedent Parainfectious COVID-19-Related GBS 14
Totale 1.664
Categoria #
all - tutte 5.013
article - articoli 4.633
book - libri 0
conference - conferenze 380
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.026


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201937 0 0 0 0 0 0 0 0 0 0 21 16
2019/2020394 17 8 11 18 27 46 69 36 37 75 40 10
2020/2021106 5 11 5 21 6 7 6 11 11 10 8 5
2021/2022239 12 9 18 24 4 17 9 66 16 18 6 40
2022/2023302 22 34 2 23 53 40 4 27 52 0 43 2
2023/2024155 6 20 7 26 17 32 28 5 7 7 0 0
Totale 1.664